Efficacy and safety of neoadjuvant treatment with liposomal doxorubicin, cyclophosphamide, paclitaxel and bevazicumab combination in locally/regionally advanced HER-2 negative, grade III premenopausal status breast cancer

Tampaki A. C.; Tampakis A.; Alifieris K.; Kontos M.; Trafalis D.

首页> 外文期刊>The Breast : >Efficacy and safety of neoadjuvant treatment with liposomal doxorubicin, cyclophosphamide, paclitaxel and bevazicumab combination in locally/regionally advanced HER-2 negative, grade III premenopausal status breast cancer

【24h】

Efficacy and safety of neoadjuvant treatment with liposomal doxorubicin, cyclophosphamide, paclitaxel and bevazicumab combination in locally/regionally advanced HER-2 negative, grade III premenopausal status breast cancer

机译：患有脂质体Doxorubicin，环磷酰胺，紫杉醇和Bevazicumab组合的Neoadjuvant治疗的疗效和安全性在局部/地区前进的HER-2阴性，III级绝育状态乳腺癌

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Breast :》 |2017年第2017期|共1页
作者
Tampaki A. C.; Tampakis A.; Alifieris K.; Kontos M.; Trafalis D.;
展开▼
作者单位

Univ Athens Sch Med Laiko Hosp Dept Propaedeut Surg 2 Athens Greece;

Univ Basel Hosp Dept Visceral Surg Basel Switzerland;

Natl Univ Athens Sch Med Dept Pharmacol Athens Greece;

Univ Athens Sch Med Laiko Hosp Dept Surg 1 Athens Greece;

Natl Univ Athens Sch Med Dept Pharmacol Athens Greece;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类胸部外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of neoadjuvant treatment with liposomal doxorubicin, cyclophosphamide, paclitaxel and bevazicumab combination in locally/regionally advanced HER-2 negative, grade III premenopausal status breast cancer [J] . Tampaki A. C., Tampakis A., Alifieris K., The Breast : . 2017,第期

机译：患有脂质体Doxorubicin，环磷酰胺，紫杉醇和Bevazicumab组合的Neoadjuvant治疗的疗效和安全性在局部/地区前进的HER-2阴性，III级绝育状态乳腺癌
2. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial [J] . Schneeweiss Andreas, Moebus Volker, Tesch Hans, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：激烈剂量 - 致密的Epirubicin，紫杉醇，环磷酰胺与每周紫杉醇，脂质体Doxorubicin（加上三重阴性乳腺癌中的Carboplatin）用于Neoadjuvant治疗高危早期乳腺癌（Geparocto-GBG 84）：随机期III试验
3. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer [J] . MonteroA.J., Diaz-MonteroC.M., DeutschY.E., Breast cancer research and treatment. . 2012,第1期

机译：NOV-002与阿霉素和环磷酰胺联合多西他赛治疗新辅助治疗HER-2阴性临床II-IIIc乳腺癌患者的2期研究
4. Acoustic Cluster Therapy displays theranostic capability in enhancing the effectiveness of liposomal doxorubicin treatment of human triple negative breast cancer in mice [C] . Nigel Bush, Andrew Healey, Anant Shah, IEEE International Ultrasonics Symposium . 2019

机译：声学聚类疗法在提高小鼠中提高人类三重阴性乳腺癌的脂质体Doxorubicin治疗的有效性方面的治疗能力
5. Natural Product Berbamine Enhances the Efficacy of Doxorubicin Treatment for Triple Negative Breast Cancer [D] . Tyler, Jake. 2020

机译：天然产品Berbamine提高了多柔比星治疗三重阴性乳腺癌的疗效
6. Phase 2 Study of Neoadjuvant Treatment with Nov-002 in Combination with Doxorubicin and Cyclophosphamide Followed By Docetaxel in Patients with HER-2 Negative Clinical Stage II-IIIc Breast Cancer [O] . AJ Montero, CM Diaz-Montero, Y Deutsch, -1

机译：第2期与Nov-002的Neoadjuvant治疗与多柔比星和环磷酰胺组合的研究其次是HER-2阴性临床II-II-II-II-II乳腺癌患者的多西紫杉醇
7. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer [O] . Lynn Symonds, Isaac Jenkins, Hannah M Linden, 2021

机译：A II期研究评估Sunitinib苹果酸的安全性和功效与每周紫杉醇组合，然后是多柔比星和每日口服环磷酰胺加G-CSF作为局部晚期或炎症乳腺癌的Neoadjuvant化疗

Efficacy and safety of neoadjuvant treatment with liposomal doxorubicin, cyclophosphamide, paclitaxel and bevazicumab combination in locally/regionally advanced HER-2 negative, grade III premenopausal status breast cancer

著录项

相似文献

相关主题

期刊订阅